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g.2013.0Abstract Purpose: The aim of this study was to demonstrate the role of interleukin-10 (IL-10)
gene polymorphism and its serum level in predicting response to treatment in patients with chronic
hepatitis C virus.
Patients and methods: This study was carried out on 35 Egyptian patients with chronic HCV
(Hepatitis C Virus) and 15 age- and sex-matched healthy subjects as control. They were divided
as follows: Group I: 35 chronic HCV patients. They were subdivided according to their response
to combination therapy of pegylated interferon alpha 2b and ribavirin into: Group I (a): 21 respon-
der patients. Group I (b): 14 non responder patients. Group II: 15 healthy subjects as a control
group. IL-10 serum level was assessed by ELISA (Enzyme Linked Immunosorbent Assay) before,
during and after treatment. IL-10 gene polymorphism and genotype were analyzed using polymer-
ase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
Results: A significant higher level of serum IL-10 was detected in HCV patients compared to the
control group. A significant reduction was detected during treatment and a persistent decrease was
found in patients with SVR. Low serum level of IL-10 pretreatment was associated with high treat-
ment response. High pretreatment of the serum level of IL-10 was associated with the severity of
chronic necroinflammation and non response to treatment. A positive correlation was found
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228 H.E. Bassat et al.in HCV patients compared to control. A significant higher frequency of the IL-10 592 C/C polymor-
phism was found in the responder group compared to non responder. No correlation was observed
between IL-10 polymorphism and liver histopathology.
Conclusion: Serum IL-10 level pretreatment is useful for predicting treatment response in HCV
patients. IL-10 may be a useful marker to assess necroinflammation and to monitor the evolution of
liver damage. IL-10 gene polymorphism has no relation to liver histopathology. IL-10 592 C/C
genotype was more frequent in responder patients.
 2013 Production and hosting by Elsevier B.V. on behalf of Ain Shams University.1. Introduction
Hepatitis C virus (HCV) infection is one of the major causes of
chronic liver disease worldwide. More than 80% of patients
with acute HCV infection become chronic, and a significant
proportion of chronic HCV patients develop cirrhosis and
even hepatocellular carcinoma in their lifetimes [1]. The mech-
anism underlying the persistence and pathogenesis is not fully
understood, but probably includes virological and immuno-
logic factors [2]. Generally, two distinct patterns of cytokine
production occur. Type I responses are characterized by pro-
duction of interleukin-2 (IL-2), tumor necrosis factor alpha
(TNF alpha) and interferon gamma, which prime and main-
tain antigen specific cellular immunity and are important in de-
fense against viruses [3,4]. Type 2 responses are characterized
by interleukin-4 (IL-4) and interleukin-10 (IL-10) production
which promote humoral immune responses [5,6]. An imbal-
ance in helper T-cell type 1 (Th1) and type 2 (Th2) cytokine
is suggested to play an important role in the pathogenesis of
chronic hepatitis C [7]. IL-10 is a Th2 cytokine produced by
monocytes, macrophages and T cells. It has potent immuno-
regulatory and anti-inflammatory properties [8]. The human
IL-10 gene is located on chromosome 1 and encodes 5 exons.
The capacity of cytokine production in an individual might
depend on a major genetic contribution. The role of IL-10
polymorphism in HCV clearance has been investigated [9,10].
The aim of this study was to demonstrate the role of inter-
leukin-10 gene polymorphism and its serum level in predicting
response to treatment in patients with chronic hepatitis C
virus.
1.1. Patients and methods
This study was carried out on 35 Egyptian patients with
chronic HCV and 15 age- and sex-matched healthy subjects
as a control group. Patients were followed up at outpatient
clinics of Tropical medicine department, Tanta University
Hospital, Tanta, Egypt during the period between May 2011
and November 2012 to assess treatment responders & non-
responders. Diagnosis of chronic HCV was based on persis-
tence of HCV antibodies and HCVRNA in the serum of the
patients for more than 6 months. Chronic hepatitis was con-
firmed by liver biopsy.
1.2. Inclusion criteria
Patients with positive HCV antibodies by ELISA and
HCVRNA by reverse transcriptase polymerase chain reaction
(RT-PCR) and histological evidence of chronic hepatitis were
included in the study.1.3. Exclusion criteria
Previous IFN-a therapy; other liver diseases such as hepatitis
A, hepatitis B, schistosomiasis, autoimmune hepatitis, alco-
holic liver disease, drug induced hepatitis, or decompensated
liver disease; coinfection with human immunodeficiency virus;
neutropenia (<1500/mm3); thrombocytopenia (<100,000/
mm3); anemia (<12 gm/dl for females and <13 gm/dl for
males), creatinine concentration >1.5 times the upper limit
of normal; serum alpha fetoprotein concentration >25 ng/
ml; organ transplant; neoplastic disease; severe cardiac or pul-
monary disease; unstable thyroid dysfunction; psychiatric dis-
order; current pregnancy or breast feeding; or therapy with
immunomodulatory agents within the last six months were
exclusion criteria.
15 healthy individuals with normal transaminase levels and
negative serologic results for hepatitis B and hepatitis C were
considered as a control group. All patients and control were
subjected to the following:
1.4. Blood sampling and laboratory tests
6 ml of blood samples was collected from each case, 3 ml was
centrifuged at a rate of 3000r/m and the serum was kept at
60 C for serological assay. The other 3 ml was used for
RT-PCR.
1.5. ELISA assay of serum IL-10 level
Serum IL- 10 level was measured by a commercially available
ELISA kit with the detection limitation of 20 pg/mL (Human
IL-10 DuoSet, R&D Systems, MN, USA) according to the
manufacturer’s instructions (10).
1.6. Quantitative assessment of HCNRNA by real time-PCR for
HCV patients
RNA extraction: RNA was extracted using QIAamp viral
RNA Kit (50) Cat. #52904 (QIAGEN).
QuantiTect Probe RT-PCR Kit (QIAGEN) was used for
quantitative, real-time, one-step RT-PCR using sequence-
specific probes.
Primers used in this research: [sense primer], 50-TGCGGAA
CCGGTGAGTACA-30 and [antisense primer],50-CTTAAGGT
TTAGGATTCGTGCTCAT-30 -Fluorogenic probe used 50-(FAM)
CACCCTATCAGGCAGTACCACAAGGCC(TAMRA)-30].
Primers are designed according to program Primer Express
(Perkin–Elmer) to design the primers and probes, following
the guidelines for the best performance of the PCR. Real-time
cycler conditions using TaqMan probes: -1-Reverse transcrip-
tion: 50 C f 30 min 2-PCR: Initial activation step: 95 C for
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ing step; Omniscript RT and Sensiscript RT are inactivated), 2-
step cycling: a-Denaturation 94 C for 15 s then b-Annealing/
Extension 60 C for 60 s. Cycle number35–45 (11).
1.7. Single nucleotide polymorphism of IL-10 promoter and
genotyping
Genomic DNA was extracted from peripheral blood leuko-
cytes using QIAamp blood kit (Qiagen, Hilden, Germany),
and quantity and purity were assessed on the basis of spectro-
scopic absorbance at 260 nm. Samples were stored at 20 C
until further use. IL-10 single nucleotide polymorphisms
(SNP) at promoter 592 site were detected by PCR using primer
that amplify a short fragment of DNA containing the poly-
morphism. The primers for 592 SNP was sense CCTAGGT-
CACAGTGACGTGG, anti-sense GGTGAGCACTACCT
GACTAGC. Amplification of the specific DNA fragments
was performed using a PTC-150 MiniCycler (MJ Research
Inc., Watertown, MA, USA) according to the following
thermocycler conditions: denaturation at 94 C for 2 min,
followed by 35 cycles of denaturation at 94 C for 30 s, anneal-
ing at 64 C for 45 s, and extension at 72 C for 1 min.
This was followed by a final extension at 72 C for 10 min.
IL-10-592A/C single nucleotide polymorphism was genotyped
by restriction fragment length polymorphism (RFLP). RFLP
assays were performed in a 20 uL reaction volume containing
PCR products and specific restriction enzyme (RsaI). In the
presence of the IL-10-592A allele, RasI cut the 412 bp PCR
product into two bands of 236 and 176 bp. The digestion prod-
ucts were stained with ethidium bromide and visualized on a
3% agarose gel [11].
1.8. Liver biopsy for HCV patients
METAVIR scoring system [11] was used to assess necroinflam-
mation and fibrosis in liver biopsy. Necroinflammation activity
(A) was graded as A0 (absent), A1 (mild), A2 (moderate), and
A3 (severe). Fibrosis stage (F) was scored as F0 (absent), F1
(portal fibrosis), F2 (portal fibrosis with few septa), F3 (septal
fibrosis) and F4 (cirrhosis) [12].
1.9. Therapeutic regimen
Pegylated interferon alpha 2b subcutaneous injection at a dose
of 1.5 lg/kg body weight per week was given in combination
with a weight adjusted dose of oral ribavirin (1000 mg/day
for <75 kg and 1200 mg/day for >75 kg) for 48 weeks. Pa-
tients were followed up at 12, 48 and 24 weeks after comple-
tion of treatment.
1.10. Treatment outcome
Patients who had undetectable HCV RNA at treatment week
12 were considered to have a complete early virological respon-
se(cEVR), while those who had P2 log reduction in
HCVRNA level compared to baseline HCVRNA level were
considered to have a partial early virological response(pEVR).
Patients who failed to clear HCVRNA from serum after
24 weeks of therapy were considered as nonresponders and
did not receive further treatment. Those patients who hadcEVR or pEVR continued treatment until 48 weeks. Patients
who had undetectable HCV RNA at the end of 48 weeks were
considered to have end treatment response (ETR) and were
followed up for 24 weeks after finishing therapy. Those pa-
tients with an undetectable HCV RNA at 24 weeks after com-
pletion of treatment were determined to have sustained
virological response (SVR). Patients with ETR in whom there
was reappearance of HCV RNA in serum during the follow-up
for 24 weeks were having relapse.
Subjects were divided into
 Group I: 35 chronic HCV patients.
 Group Ia: 21 responder patients.
 Group Ib: 14 non responder patients.
 Group II: 15 healthy persons as control.
All patients and control gave their informed consent and
the study was approved by Ethical, and Research Committee,
Tanta Faculty of Medicine, Tanta, Egypt.
1.11. Statistical analysis
The statistical data are reported as the mean ± SD, frequen-
cies (number) and percentages when appropriate. A compari-
son of numerical variables between the study groups was
performed using Student’s t-test to compare independent sam-
ples from two groups when the samples were normally distrib-
uted and the Mann–Whitney U-test to compare independent
samples when the samples were not normally distributed. A
comparison of the numerical variables between more than
two groups was performed using a one-way analysis of vari-
ance test to compare normal data, and the Kruskal–Wallis test
was used when the data were not normal. To compare categor-
ical data, a v2 test was performed. The accuracy is represented
using the terms sensitivity and specificity. Spearman rank cor-
relation was used to quantify the association between continu-
ous or ordered categorical variables. A receiver operator
characteristic (ROC) analysis was used to determine the opti-
mum cut-off value for the studied prognostic markers. P-val-
ues less than 0.05 were considered statistically significant. All
statistical calculations were performed using the computer pro-
gram SPSS (Statistical Package for the Social Science; SPSS,
Chicago, IL, USA) version 15 for Microsoft Windows.
2. Results
The results of this study showed that there was no statistical
difference between HCV patients and control as regards age
and gender (P > 0.05), significant higher level of the serum
ALT and AST in patients with HCV compared to the control
group (P < 0.05), and the frequency of the IL-10 592 genotype
and IL-10 serum level was significantly higher in HCV patients
compared to control (P < 0.05) (Table 1).
Also, the results of the present study showed a significant
higher frequency of the IL-10 592 C/C genotype in responder
patients compared to nonresponders. IL-10 base line serum le-
vel was significantly lower in responders than nonresponder
patients. Liver histopathology revealed a significant higher
grading of necroinflammation in non responder than respon-
der patients. No significant difference was detected as regards
fibrosis between responders and nonresponders (Table 2).
Table 1 Baseline parameters in both HCV patients and control groups.
HCV n= 35 Control n = 15 P
Age 39.7 ± 1.8 41 ± 6.4 >0.05
Sex(M/F) 24/11 10/5 >0.05
ALT(U/L) 61.3 ± 12.3 26.2 ± 4.1 <0.05*
AST(U/L) 52.4 ± 11.4 24.1 ± 5.7 <0.05*
Bilirubin (mg/dl) 1.3 ± 0.5 0.8 ± 0.2 >0.05
Albumin (g/dl) 3.9 ± 0.7 4.3 ± 0.4 >0.05
PT (seconds) 12.1 ± 1.4 11 ± 0.5 >0.05
HCV ANA (106 copies/ml) 6.9 ± 6.5 – –
Serum. IL-10 (pg/ml) 68.1 ± 24.5 46.9 ± 16.2 <0.05*
IL-10 592 genotype n (%)
A/A 11 (31.4%) 7 (46.7%)
A/C 10 (28.6%) 6 (40%) <0.05*
C/C 14 (40%) 2 (13.3%)
Table 2 IL-10 genotypes, IL-10 serum level and liver histopathology in responders and nonresponders of HCV patients.
Responders n= 21 Non responders n= 14 P-value
IL-10 genotype
A/A 4 (19.1%) 7 (50%) 0.033*
A/C 4 (19.1%) 6 (42.9%)
C/C 13 (61.9%) 1 (7.1%)
Serum. IL10 (pg/ml) (median) 56 79.5 0.013*
Histopathological activity
METAVIR activity grade
Mild (A1) 15 (71.4%) 1 (7.14%) 0.019*
Moderate (A2) 4 (19.1%) 5 (35.71%)
Severe (A3) 2 (9.5%) 8 (57.14%)
METAVIR fibrosis stage
F1 14 (66.7%) 3 (21.4%) >0.05
F2 5 (23.8%) 5 (35.7%)
F3 2 (9.2%) 6 (42.9%)
IL, interleukin; *P < 0.05 significant.
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serum level at 12, 48, and 72 weeks of treatment in responders
(Table 3).
As regards different laboratory parameters and liver histo-
pathology, a significant positive correlation was detected be-
tween severe grading of necroinflammation and each of IL-
10, ALT, where as no significant correlation was found be-
tween IL-10 gene polymorphism and either necroinflammation
or fibrosis (Table 4).
The present study revealed 95.5% sensitivity and 100%
specificity of IL-10 as a prognostic marker for evaluation of re-
sponse to interferon and ribavirin therapy (Table 5).
3. Discussion
IL-10 level differs widely between individuals probably due to
polymorphism in the promoter region. This region includes
two informative microsatellites and three frequent point muta-
tions 1082(G/A, 819(C/T), and 592(C/A). The 1082(G),
819(G) and 592(C) alleles were associated with higher IL-10
production. The -1082(G/G genotype is known to be related
to increase IL-10 production and is associated with a high risk
of inefficient HCV clearance [13,14] and resistance to inter-feron therapy [13,14]. Recent study indicated that polymor-
phism of the promoter region of IL-10 gene (ATA
haplotype) may determine spontaneous clearance of HCV
infection [17].
This study revealed a significant higher serum level of IL-10
in HCV patients compared to control group. This was in
accordance with Yoneda et al. [18], Shaker et al. [19] and sev-
eral other studies [20,21], which reported a significant increase
of the IL-10 level in the serum of HCV patients. In contrast,
Marcello et al. [22] demonstrated no significant difference in
the serum level of IL-10 between HCV patients and healthy
control that is due to a different genotype of HCV included
in this study. This study demonstrated a decrease in the serum
level of IL-10 during treatment and remained low in patients
with sustained virological response (SVR). These findings sug-
gest that cytokines may in fact compromise host immune re-
sponse to the virus .This was in agreement with Yoneda
et al. [18], who reported decreased cytokine levels of IL-10,
IL-12 and IL-18 during treatment with interferon and
ribavirin.
This study demonstrated a significant low base line in the
serum level of IL-10 in the responder group compared to
non responder. Also, Shaker et al. [19] reported a significant
Table 4 Correlation between liver histopathology and serum
parameters in HCV patients.
Inflammation Fibrosis
R P-value R P-value
S. IL-10 (pg/ml) 0.519 0.002* 0.572 0.742
AST U/L 0.255 0.137 0.182 0.294
ALT U/L 0.528 0.001* 0.263 0.126
IL-10 592 genotype 0.195 0.259 0.119 0.503
IL, interleukin, *P< 0.05 significant.
Table 3 IL-10 serum level changes before, during and after treatment.
Treatment outcome Baseline 12 week 48 week 72 week P-value
Responders 56 pg/ml 42 32 30 <0.001*
Non responders 79.5 77.5 78 76.5 >0.05
Data are median values. IL, interleukin; *P < 0.05 significant.
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ment with the present study Yoneda et al. [18] revealed a
strong association between high base line serum IL-10 and a
non response to interferon and ribavirin therapy. An associa-
tion between low base line serum IL-10 and response to treat-
ment was also reported by some previous studies [23–25].
Although humoral immunity is said to play a major role in
recovery from HCV infection and B-cell is the strongest in
those with persistent infection [26,27], a strong natural killer
cell mediated and Th1 cell mediated immune response seems
to be a key factor in protection from HCV infection [27].
This study demonstrated that the low IL-10 level before
treatment was associated with SVR. This cytokine may offer
the clinician another tool in predicting treatment outcome of
HCV infection. It may be concluded that HCV patients who
are genotyped as high IL-10 producers have a poor response
to interferon therapy, these patients may therefore benefit from
additional treatment strategies designated to enhance Th1 re-
sponses [28].
As regards liver histopathology, in this study serum IL-10
showed a significant positive correlation with METAVIR
activity grade. This was in accordance with Marcello et al.
[22] who found a significant higher level of IL-10 in patients
with a grading score of 9–18 than in those with 1–8 grading
score in HAI. In contrast, another study [29] reported no cor-
relation between IL-10 and liver histology, ALT, age, sex and
viral load. This can be explained by different genotypes of
HCV. This study found no significant correlation between
serum IL-10 value and the degree of fibrosis. This was in accor-
dance with Lin et al. [30] and Marcello et al. [22], who
observed absence of any relationship between IL-10 and
staging score of fibrosis.Table 5 Cutoff value, sensitivity, specificity, AUC, PPV and NPV
Cutoff value Sensitivity (%) Specificity (%)
70.3 pg/ml 95.5 100
PPV: positive predictive value, NPV: negative predictive value, AUC.An experimental study conducted on animal models
showed that IL-10 blockade strategy is capable of ameliorating
the outcome of chronic viral infection [31,32]. IL-10 contrib-
utes to reduce the pathogenic effects of infection for the price
of a weakening of the immune response aimed at the eradica-
tion of the virus and that timing as well as the relative amounts
of IL-10 production is critical for safe resolution of infection
[22]. It has also been reported that the heterozygous C/A var-
iant in the IL-10 gene promoter region C592A is associated
with a major risk of progression and chronic course of viral
hepatitis [33]. Alteration of host immune system due to genetic
predisposition determines the switch in the predominant acti-
vation from Th1 to Th2 cells with a consequent imbalance in
the production of immunoregulatory cytokines. Such imbal-
ances could determine a greater increase in IL-10 concentra-
tion, leading to impaired viral clearance and persistent
necroinflammation [22].
This study demonstrated positive correlation between IL-10
values and serum ALT while no correlation was found with
AST. Some other studies also reported the reduction in trans-
aminase level was associated with a decrease in the IL-10 level
in patients with chronic HCV treated with interferon and riba-
virin [20,21]. In contrast Marcello et al. [22] reported a signif-
icant correlation between AST and IL-10 .
The association of the severity of liver disease and cytokine
polymorphism was assessed in this study. IL-10 polymorphism
did not show any significant association with either necroin-
flammation grading or fibrosis staging. This was in agreement
with Chuang et al. [34] and Abott et al. [35], who found no cor-
relation between IL-10 gene polymorphism and liver histopa-
thology as regards necroinflammation and fibrosis. Genetic
study of the IL-10 gene polymorphism in HCV has also been
reported in other studies [36,15], suggesting that it has no role
in the development of hepatic fibrosis. Dogra et al. [37] re-
corded the absence of correlation between IL-10 polymor-
phism and the severity of liver disease.
This study revealed that SVR at the end of treatment was ob-
tained at 60%while non responsewas detected in 40%.This was
in accordance with Slenzer et al. [38], Kurbanoy et al. [39] and
Shaker et al. [19]. The frequency of the IL-10 592 genotype poly-
morphism was higher in HCV compared to control. This was in
agreement with Shaker et al. [19], who reported a significant
higher frequency of the IL-10 592 genotype polymorphism in
HCV patients than control. In contrast Dogra et al. [37] and
Chuang et al. [32] demonstrated no significant difference inof serum IL-10 level as prognostic marker in HCV patients.
PPV (%) NPV (%) AUC
100 92.9 0.95
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This can be explained by different virus genotypes.
Our study recorded a significant higher frequency of IL-10
592 C/C in responders compared to non responders (61.9% Vs
7.1%) respectively. This was similar to the results reported by
Shaker et al. [19]. In contrast, Chang et al. [34] found a higher
frequency of the IL-10 genotype AC and GG in responders
compared to non responders. The patients enrolled in their
study were with genotypes 1 and 2.
4. Conclusions
Serum IL-10 pretreatment level is considered a good predictive
non invasive marker to predict response to interferon and riba-
virin therapy in HCV patients. The IL-10 592 C/C genotype
polymorphism is associated with response to treatment in
HCV patients.References
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